淫羊藿苷
骨质疏松症
药物输送
药理学
间充质干细胞
骨重建
医学
药品
体内
骨组织
化学
内科学
生物医学工程
病理
生物
生物技术
有机化学
替代医学
作者
Gan Luo,Ze-Han Wang,Hou-zhi Yang,Yonggang Fan,Ze-Tao Jiang,Yu-Qiao Li,Hai-Yang Cheng,Ji-Geng Fan,Shanshan Li,Qiong Tang,Xin Jin,Dong‐Sheng Guo,Tianwei Sun
标识
DOI:10.1016/j.ijpharm.2024.124457
摘要
Osteoporosis, a prevalent systemic bone metabolic disorder, primarily affects postmenopausal women and is characterized by increased bone fragility and a heightened risk of fractures. The efficacy of current osteoporosis treatments is often limited by non-specific drug targeting and undesirable off-target skeletal side effects. To address this challenge, we have developed a novel hydroxyapatite-responsive drug delivery system. This system utilizes a self-assembled p-phosphonatocalix[4]arene tetradodecyl ether (PC4A12C), engineered to specifically target and sustain the release of osteoporosis medication at sites of bone remodeling. Our focus centers on icariin (ICA), a drug known for its potent osteogenic properties and minimal adverse effects. In vitro, ICA-loaded PC4A12C (ICA@PC4A12C) demonstrated enhanced proliferation, differentiation, and mineralization in bone marrow mesenchymal stem cells (BMSCs). In vivo, ICA@PC4A12C exhibited superior efficacy in specifically targeting bone tissue, ensuring a controlled and slow release of icariin directly within the bone environment. In an osteoporosis mouse model, treatment with ICA@PC4A12C showed notable enhancement in osteogenic activity and a significant increase in bone density compared to ICA alone. These results demonstrate the potential of PC4A12C as an effective drug carrier in the development of advanced antiosteoporotic drug delivery systems.
科研通智能强力驱动
Strongly Powered by AbleSci AI